Ownership history in Prosight Management, LP Β· 7 quarters on record
This page tracks every 13F SEC filing in which Prosight Management, LP reported a position in AILERON THERAPEUTICS INC (RNTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Prosight Management, LP underperformed the S&P 500 by β92.5% annually on this RNTX position. Timing score: 40% (2/5 decisions correct). Average cost basis: $2.16. Maximum drawdown during holding period: β67.8%.
β Significantly underperformed the S&P 500 by 92.5% ann.
5 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 5 add/trim decisions correct
Best entry: $1.14 (2025 Q3) Β· Worst: $3.54 (2024 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 2 trims. Bought during 3 of 4 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.11% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size